Pravastatin Effects on Placental Prosurvival Molecular Pathways in a Mouse Model of Preeclampsia

Reproductive Sciences

Volumn 23, Issue 11, 2016, Pages 1593-1599

  Saad, Antonio F ^a   Diken, Zaid M ^a   Kechichian, Talar B ^a   Clark, Shannon M ^a   Olson, Gayle L ^a   Saade, George R ^a   Costantine, Maged M ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

MAPK; placenta; pravastatin; preeclampsia; stress induced survival

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 2; HEAT SHOCK PROTEIN 27; IMMUNOGLOBULIN G2A; MITOGEN ACTIVATED PROTEIN KINASE; PLACENTA PROTEIN; PRAVASTATIN; STAT2 PROTEIN; STAT3 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN; FLT1 PROTEIN, MOUSE; HSPB2 PROTEIN, MOUSE; STAT3 PROTEIN, MOUSE; VASCULOTROPIN RECEPTOR 1;

ADENOVIRIDAE; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BIRTH WEIGHT; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; FEMALE; GESTATIONAL AGE; IN VIVO STUDY; LITTER SIZE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PLACENTA; PLACENTA WEIGHT; PREECLAMPSIA; PREGNANCY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL; ANIMAL; DISEASE MODEL; DRUG EFFECTS; MAPK SIGNALING; METABOLISM; PHOSPHORYLATION; PRE-ECLAMPSIA;

ANIMALS; APOPTOSIS; DISEASE MODELS, ANIMAL; FEMALE; HSP27 HEAT-SHOCK PROTEINS; MAP KINASE SIGNALING SYSTEM; MICE; PHOSPHORYLATION; PLACENTA; PRAVASTATIN; PRE-ECLAMPSIA; PREGNANCY; STAT3 TRANSCRIPTION FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84991383940     PISSN: 19337191     EISSN: 19337205     Source Type: Journal    
DOI: 10.1177/1933719116648218     Document Type: Article

References (36)

1. ACOG Committee on Practice Bulletins-Obstetrics. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. Obstet Gynecol. 2002; 99 (1): 159-167.
2. Costantine MM, Cleary K, Eunice Kennedy Shriver National Institute of Child Health and Human Development Obstetric-Fetal Pharmacology Research Units Network. Pravastatin for the prevention of preeclampsia in high risk pregnant women. Obstet Gynecol. 2013; 121 (2 pt 1): 349-353.
3. Lu F, Bytautiene E, Tamayo E, et al. Gender-specific effect of overexpression of SFlt-1 in pregnant mice on fetal programming of blood pressure in the offspring later in life. Am J Obstet Gynecol. 2007; 197 (4): 418. e1-e5.
4. Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003; 111 (5): 649-658.
5. Saad AF, Kechichian T, Yin H, et al. Effects of pravastatin on angiogenic and placental hypoxic imbalance in a mouse model of preeclampsia. Reprod Sci. 2014; 21 (1): 138-145.
6. Costantine MM, Tamayo E, Lu F, et al. Using pravastatin to improve the vascular reactivity in a mouse model of soluble fms-Like tyrosine kinase-1-induced preeclampsia. Obstet Gynecol. 2010; 116(1): 114-120.
7. Fox KA, Longo M, Tamayo E, et al. Effects of pravastatin on mediators of vascular function in a mouse model of soluble fms-like tyrosine kinase-1-induced preeclampsia. Am J Obstet Gynecol. 2011; 205 (4):366. e1-e5.
8. Ahmed A, Singh J, Khan Y, Seshan SV, Girardi G,. A new mouse model to explore therapies for preeclampsia. PLoS One. 2010; 5 (10): e13663.
9. Kumasawa K, Ikawa M, Kidoya H, et al. Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model. Proc Natl Acad Sci of the U S A. 2011; 108 (4): 1451-1455.
10. Singh J, Ahmed A, Girardi G,. Role of complement component C1q in the onset of preeclampsia in mice. Hypertension. 2011; 58 (4): 716-724.
11. Torry DS, Mukherjea D, Arroyo J, Torry RJ,. Expression and function of placenta growth factor: implications for abnormal placentation. J Soc Gynecol Invest. 2003; 10 (4): 178-188.
12. Levine RJ, Lam C, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004; 350 (7): 672.
13. Levine RJ, Lam C, Qian C, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med. 2006; 355 (10): 992-1005.
14. Berends AL, de Groot CJ, Sijbrands EJ, et al. Shared constitutional risks for maternal vascular-related pregnancy complications and future cardiovascular disease. Hypertension. 2008; 51 (4): 1034-1041.
15. Shi GX, Jin L, Andres DA,. A Rit GTPase-p38 mitogen-activated protein kinase survival pathway confers resistance to cellular stress. Mol Cell Biol. 2011; 31 (10): 1938-1948.
16. Yano M, Matsumura T, Senokuchi T, et al. Statins activate peroxisome proliferator-activated receptor through extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase-dependent cyclooxygenase-2 expression in macrophages. Circ Res. 2007; 100 (10): 1442-1451.
17. Takenouchi Y, Kobayashi T, Matsumoto T, et al. Possible involvement of Akt activity in endothelial dysfunction in type 2 diabetic mice. J Pharmacol Sci. 2008; 106 (4): 600-681.
18. Shiota M, Hikita Y, Kawamoto Y, et al. Pravastatin-induced proangiogenic effects depend upon extracellular FGF-2. J Cell Mol Med. 2012; 16 (9): 2001-2009.
19. Chen JC, Huang KC, Lin WW,. HMG-CoA reductase inhibitors upregulate heme oxygenase-1 expression in murine RAW264.7 macrophages via ERK, p38 MAPK and protein kinase G pathways. Cell Sign. 2006; 18 (1): 32-39.
20. Hinkelmann U, Grosser N, Erdmann K, Schröder H, Immenschuh S,. Simvastatin-dependent up-regulation of heme oxygenase-1 via mRNA stabilization in human endothelial cells. Eur J Pharm Sci. 2010; 41 (1): 118-124.
21. Cudmore M, Ahmad S, Al-Ani B, et al. Negative regulation of soluble flt-1 and soluble endoglin release by heme oxygenase-1. Circulation. 2007; 115 (13): 1789-1797.
22. Nadeau V1, Charron J,. Essential role of the ERK/MAPK pathway in blood-placental barrier formation. Development. 2014; 141 (14): 2825-2837. doi:10.1242/dev.107409.
23. Torry DS, Mukherjea D, Arroyo J, Torry RJ,. Expression and function of placenta growth factor: implications for abnormal placentation. J Soc Gynecol Investig. 2003; 10 (4): 178-188.
24. Breitwieser W, Lyons S, Flenniken AM, et al. Feedback regulation of p38 activity via ATF2 is essential for survival of embryonic liver cells. Genes Dev. 2007; 21 (16): 2069-2082.
25. San Martin S, Fitzgerald JS, Weber M, et al. STAT3 and SOCS3 expression patterns during murine placenta development. Eur J Histochem. 2013; 57 (2): e19.
26. Rana S, Rajakumar A, Geahchan C, et al. Ouabain inhibits placental sFlt1 production by repressing HSP27 dependent HIF-1 α pathway. FASEB J. 2014; 28 (10): 4324-4334.
27. Ofori B, Rey E, Berard A,. Risk of congenital anomalies in pregnant users of statin drugs. Br J Clin Pharmacol. 2007; 64 (4): 496.
28. Taguchi N, Rubin ET, Hosokawa A, et al. Prenatal exposure to HMG-CoA reductase inhibitor: effects on fetal and neonatal outcomes. Reprod Toxicol. 2008; 26 (2): 175.
29. Petersen EE, Mitchell AA, Carey JC, et al. Maternal exposure to statins and risk for birth defects. Am J Med Gen. 2008; 146A (20): 2701-2705.
30. Winterfeld U, Allignol A, Panchaud A, et al. Pregnancy outcome following maternal exposure to statins: a multicentre prospective study. Br J Obstet Gynaecol. 2013; 120 (4): 463-471.
31. Bateman BT, Hernandez-Diaz S, Fischer MA, et al. Statins and congenital malformations: cohort study. BMJ. 2015; 350: h1035.
32. Zarek J, Degorter MK, Lubetsky A, et al. The transfer of pravastatin in the dually perfused human placenta. Placenta. 2013; 34 (8): 719-721.
33. Nanovskaya TN, Patrikeeva SL, Paul J, Costantine M, Hankins GDV, Ahmed MS,. Transplacental transfer and distribution of pravastatin. Am J Obstet Gynecol. 2013; 209 (4): 373. e1-5.
34. Woollett LA,. Maternal cholesterol in fetal development: transport of cholesterol from the maternal to the fetal circulation. Am J Clin Nutr. 2005; 82 (6): 1155-1161.
35. Ethier-Chiasson M, Duchesne A, Forest JC, et al. Influence of maternal lipid profile on placental protein expression of LDLr and SR-BI. Biochem Biophys Res Commun. 2007; 359 (1): 8-14.
36. Kazmin A, Garcia-Bournissen F, Koren G,. Risks of statin use during pregnancy: a systematic review. J Obstet Gynaecol Can. 2007; 29 (11): 906-908.